Synthes’ relationship with surgeons questioned
The News Review:
- Synthes’ relationship with surgeons questioned
- goBalto Partners with Pharma Services Network to Help Sponsors …
- Microsoft Announces Winners of the 2009 Pharmaceutical and Life …
- PicksThatMove: www.PicksThatMove.com: www.PicksThatMove.com: www …
- Redesigned Corporate Identity and nowEDC Software Upgrade Reflect …
- Clinipace Extends Partnership with the ImproveCareNow …
- Advaxis Engages the Numoda Corporation to versee Phase II …
Synthes’ relationship with surgeons questioned
Philadelphia Inquirer
Federal law requires that patients involved in research give informed consent which includes making sure the patient understands the risks involved in experimental procedures. It is not clear that patients knew the risks in using Norian XR in these surgeries. "Informed consent is a bedrock principle of clinical research" said Hal Sox editor of the Annals of Internal Medicine a medical journal published in Philadelphia. ne of the surgeons whose patient died told Synthes executives that he had "noticed a cement leak during injection and feels this was the cause of the incident" according to the indictment. The surgeon complained that a Synthes "sales consultant pushed this product on him and was unclear as to its status on the market. "Synthes executives allegedly failed to report the first patient death to the FDA as required by law and left out key details when they reported the two other deaths to hide off-label promotion of Norian XR the indictment said. In November 2004 Synthes told the FDA it was going to take Norian XR off the market.
goBalto Partners with Pharma Services Network to Help Sponsors …
PR Web (press release)
Since launching in April goBalto has listed more than 7000 businesses which represent clinical research investigator sites generic suppliers contract manufacturers and consulting professionals from all over the world. According to Pharma Services Netowork pharmaceutical and biotech developers in the USA spend more than $10 billion annually to outsource clinical studies of new drug compounds. That represents more than half of the entire global market. A growing percentage of the outsourcing dollars are being spent abroad particularly in emerging markets like Brazil Russia India and China. Pharma Services Network specializes in connecting sponsors to quality service providers in these distant markets.
Microsoft Announces Winners of the 2009 Pharmaceutical and Life …
PR Newswire (press release)
As a result the Data Intelligence SQL Server-based solution has enabled the staff to quickly respond to new business challenges and opportunities. In addition over 200 sales representatives now have immediate access to their sales performance by account. — Clinical Development: Harvard Clinical Research Institute The Harvard Clinical Research Institute advances research by facilitating more efficient collaboration between the industry and academia. A highly respected academic research organization (AR) the Harvard Clinical Research Institute needed to aggregate data from multiple sources into one to generate increased efficiency and productivity. The Harvard Clinical Research Institute will make more information available to study constituents and respond more capably to a growing number of research centers around the world. The Harvard Clinical Research Institute deployed TranSenda’s ffice-Smart Clinical Trial Manager (SCTM) in order to access critical operational data from disparate systems and multiple clinical trials and manage it into a single source. The deployment of SCTM with its native interoperability with the Microsoft ffice SharePoint System resulted in a streamlined processing of operational data management significantly reducing the amount of time and effort involved in each study.
PicksThatMove: www.PicksThatMove.com: www.PicksThatMove.com: www …
Trading Markets (press release)
The Empirica Study solution helps clinical and safety teams improve their understanding of a product’s emerging safety profile during clinical development by facilitating the timely detection review and analysis of safety issues in clinical trials data. About Phase ForwardPhase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward’s products and services have been utilized in over 10000 clinical trials involving more than 1000000 clinical trial study participants at over 290 organizations and regulatory agencies worldwide including: AstraZeneca Boston Scientific Dana-Farber Cancer Institute Eli Lilly the U. Food and Drug Administration GlaxoSmithKline Harvard Clinical Research Institute Merck Serono Novartis Novo Nordisk PAREXEL International Procter & Gamble Quintiles sanofi-aventis Schering-Plough Research Institute Servier Tibotec and the U. Medicines and Healthcare Products Regulatory Agency.
Related from Murtoughsupply: PicksThatMove: Data Domain Inc. (NASDAQ: DDUP) We have picks that …
Redesigned Corporate Identity and nowEDC Software Upgrade Reflect …
PR Newswire (press release)
“Not only do we have the flexibility to deliver both paper and EDC studies but we also possess the wisdom to recommend the best approach for their specific needs. Should those needs dictate that nowEDC is the best solution for them they’ll know that they’re getting a version that is fast easily deployed and user-friendly. The redevelopment of nowEDC aims to make it even easier for customers to use and even faster to get real-time data from their clinical research while the logo and messaging demonstrate that Datatrial is responsive to the ever-changing clinical research industry–and its ever-improving place within it. Combined these latest moves highlight the company’s dedication to serving its customers and partners with maximum efficiency and minimum stress. “In the current economic climate there is more pressure on clinical research companies to design studies that make sense from both time and budgetary standpoints” said Black. “Meeting those demands has been made easier by the fact that we choose the companies that have the same team-oriented approach as us–so each customer is our most important customer. And because we treat them as part of the team we are as invested as they are in their clinical trial.
Clinipace Extends Partnership with the ImproveCareNow …
Business Wire (press release)
The initial focus has been to build a quality improvement infrastructure at each site; to develop and implement the recommendations of the ImproveCareNow Model IBD Care Guideline; to measure and report the performance at each site and all sites; to identify gaps between the recommended care and the care actually provided; and to implement quality improvement projects to close the gaps. After 2 years the ImproveCareNow has demonstrated the effectiveness of quality improvement in improving care and outcomes in a chronic illness. About Clinipace Clinipace an experienced digital clinical research organization (dCR) provides on-demand software and clinical services for phase I-IV clinical trials registries and investigator-initiated grant management programs. We serve biopharmaceutical and medical device companies as well as academic medical centers. ptimized by TEMP™ our web-based software platform we deliver clinical trial and registry services at up to a 30% savings compared to traditional service providers. Learn more at.
Advaxis Engages the Numoda Corporation to versee Phase II …
MarketWatch
91%) has engaged the Numoda Corporation a leading clinical trial and logistics management company to oversee Phase II clinical activity with ADXS11-001 for the treatment of invasive cervix cancer and cervical intraepithelial neoplasia (CIN; cervical dysplasia). Numoda will integrate oversight and logistical functions with the clinical research organizations (CR) contract laboratories academic laboratories and statistical groups involved. “The Numoda Corporation offers experience and resources that will enable Advaxis to execute multiple high quality clinical trials with precision efficiency high quality data and a rapid final study report” commented Advaxis EVP of Science and perations Dr. Advaxis anticipates that the Numoda Corporation’s involvement will help expedite the clinical trial process. The Company anticipates initiating trial activity in September 2009 as described and delineated in the Company’s most recent 10-Q filing.
Written by admin on June 23rd, 2009 with
no comments.
Read more articles on News.